2017-05-12T19:03:35-05:00 2016-06-30 941254756 HOOD & STRONG LLP 275 BATTERY ST STE 900 SAN FRANCISCO CA 94111 990 2015-07-01 030485196 MYELIN REPAIR FOUNDATION MYEL 4088712410 20111 EDINBURGH DRIVE SARATOGA CA 95070 SCOTT JOHNSON PRESIDENT 4088712410 2017-05-12 1 MAGA E KISRIEV P01008919 4157810793 2015 2021-01-29 14:40:06Z SCOTT JOHNSON 20111 EDINBURGH DRIVE SARATOGA CA 95070 576238 0 X WWW.MYELINREPAIR.ORG X 2002 CA ACCELERATING THE DEVELOPMENT OF NEW THERAPEUTICS TO PREVENT OR REPAIR DAMAGE TO MYELIN CAUSED BY MS. 6 5 15 5 0 0 2660020 216766 0 0 -10708 9472 106579 350000 2755891 576238 393504 0 0 0 1961438 534461 0 0 18144 3269868 279595 5624810 814056 -2868919 -237818 1355841 834421 281806 115 1074035 834306 X TO ACCELERATE THE DEVELOPMENT OF NEW THERAPEUTICS TO PREVENT OR REPAIR DAMAGE TO MYELIN CAUSED BY MULTIPLE SCLEROSIS. THE MYELIN REPAIR FOUNDATION (MRF) DRIVES BASIC RESEARCH, TRANSLATES DISCOVERIES AND PARTNERS WITH COMPANIES AND GOVERNMENT TO ENSURE TREATMENTS GET RAPIDLY TO PATIENTS. 0 1 661638 0 350000 DISCOVERY BIOLOGY: MRF STOPPED FUNDING ITS WORLDWIDE COLLABORATIVE DISCOVERY BIOLOGY TEAM. TO BRING THESE ACTIVITIES TO A SMOOTH CONCLUSION MRF HOSTED A FINAL ANNUAL IN-PERSON TWO DAY MEETING OF THE TEAM. MRF ALSO TURNED THE PORTFOLIO OF PATENTS THAT HAD RESULTED FROM ACADEMIC RESEARCH IT HAD FUNDED, OVER TO THE APPROPRIATE UNIVERSITIES. TRANSLATIONAL MEDICINE: MRF CLOSED ITS TRANSLATIONAL MEDICINE CENTER (TMC), BUT BEFORE DOING SO, MRF SOUGHT OTHER NON-PROFITS, ACADEMICS AND COMPANIES TO TAKE OVER RUNNING THE HIGHLY SOPHISTICATED AND COMPLEX ASSAYS THAT MRF HAD DEVELOPED. TO DO SO MRF BROADLY OFFERED TO DEMONSTRATE AND TO TRAIN OTHERS HOW TO PERFORM THE SUITE OF ASSAYS. TEVA PHARMACEUTICALS EXPRESSED INTEREST, OVER A THREE MONTH PERIOD THEY LEARNED HOW TO PERFORM THE ASSAYS AND TRANSFERRED THEM TO THEIR OWN LAB FOR FURTHER MYELIN REPAIR RESEARCH. TEVA HAS STATED THAT THEY VIEW THEMSELVES AS STEWARDS OF THE ASSAYS. WHILE THE ASSAYS ARE HOUSED IN THEIR LAB, THEY SEE THE ASSAYS AS A VALUABLE PLATFORM THAT THEY WILL BE HAPPY TO SHARE WITH THE MYELIN REPAIR COMMUNITY TO ADVANCE NEW TREATMENTS. MRF STAFF WROTE, SUBMITTED FOR PUBLICATION, AND HAD PUBLISHED FOUR TECHNICAL PAPERS ABOUT MRF'S ASSAYS AND THE RESULTS OF THE DRUG SCREENING CONDUCTED BY MRF AT THE TMC. TO MAKE OUR SCREENING DATA BROADLY AVAILABLE TO THE SCIENTIFIC COMMUNITY WE POSTED IT ONLINE. WE ALSO COMPLETED A LICENSE AGREEMENT WITH A COMPANY THAT HOPES TO MOVE SOME OF OUR SCIENCE TOWARD THE CLINIC. CLINICAL: UNDER THE COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT SIGNED IN 2013, MRF WORKED WITH THE NATIONAL INSTITUTES OF HEALTH (NIH) TO CONDUCT A PHASE 1 CLINICAL TRIAL. HUMAN PATIENTS WERE SELECTED, ENROLLED, TREATED, AND DATA GATHERED. 661638 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 22 0 1 15 1 0 0 0 0 0 1 1 0 0 0 0 0 X 6 5 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X X MARY LACHNIT 4088712410 20111 EDINBURGH DRIVE SARATOGA CA 95070 SHARON WIENBAR BOARD MEMBER 1.00 X 0 0 0 CASEY MCGLYNN BOARD MEMBER 1.00 X 0 0 0 BOBBY MEHTA BOARD MEMBER 1.00 X 0 0 0 ANDY CATES BOARD MEMBER 1.00 X 0 0 0 JIM GIDWITZ BOARD MEMBER 1.00 X 0 0 0 SCOTT JOHNSON CEO 40.00 X X 257916 0 9928 JAY TUNG VP DRUG DISCOVERY (THRU 11/30/15) 40.00 X 263356 0 10331 DENISE ST ONGE CFO 5.00 X 27900 0 0 TASSIE COLLINS DIRECTOR (THRU 10/22/15) 40.00 X 181700 0 4694 MARY LACHNIT CONTROLLER 32.00 X 107124 0 9006 ELEN ROSLER SCIENTIST (THRU 10/23/15) 40.00 X 106554 0 3113 KAREN LARIOSA-WILLINGHAM SCIENTIST (THRU 11/30/15) 40.00 X 123624 0 168 1068174 0 37240 6 0 1 0 0 216766 216766 9472 0 9472 9472 9472 RESEARCH INCOME 900099 350000 350000 350000 576238 350000 0 9472 352295 292474 46527 13294 116115 82641 33474 50151 37069 13082 15900 10685 5215 10750 10750 435 435 28303 14440 13863 17048 7669 6102 3277 799 799 73554 71964 1005 585 20723 16278 3457 988 ANNUAL RESEARCH MEETING 61849 61849 CONTRACT RESEARCH 51299 51299 TRANSLATIONAL MEDICINE 14662 14662 EXCHANGE GAIN/LOSS 173 173 814056 661638 134274 18144 801925 829924 450000 0 0 721 20510 3776 0 0 40495 0 42911 0 1355841 834421 205448 115 76358 0 281806 115 X 450000 834306 624035 0 1074035 834306 1355841 834421 -237818 -1911 0 X 0 0 0 X 1761904 4428671 3463318 2660019 216766 12530678 1761904 4428671 3463318 2660019 216766 12530678 5079491 7451187 7382 4420 1256 392 0 13450 67204 19500 21665 106579 214948 12759076 350000 0.58400 0.60740 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2011 AMOUNT: $ 67,204. 2012 AMOUNT: $ 19,500. 2013 AMOUNT: $ 21,665. 2014 AMOUNT: $ 40. 2015 AMOUNT: $ 0. REIMBURSED LEGAL FEES - 2014 AMOUNT: $ 106,539. 2015 AMOUNT: $ 0. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 0 1 X X X X 0 0 0 0 0 0 0 0 0 SCOTT JOHNSON CEO 194775 0 22500 0 40641 0 0 0 9928 0 267844 0 0 0 JAY TUNG VP DRUG DISCOVERY (THRU 11/30/15) 207717 0 25383 0 30256 0 0 0 10331 0 273687 0 0 0 TASSIE COLLINS DIRECTOR (THRU 10/22/15) 154461 0 15879 0 11360 0 0 0 4694 0 186394 0 0 0 PART I, LINE 1A MR. JOHNSON HAS MULTIPLE SCLEROSIS AND REQUIRES ASSISTANCE WHEN HE TRAVELS. MRF PAYS FOR HIS WIFE TO ACCOMPANY HIM ON BUSINESS TRIPS. FORM 990, PART III, LINE 3 BECAUSE OF REDUCED FUNDS RAISED, IT WAS NECESSARY FOR MRF TO GREATLY SCALE BACK ITS PROGRAM ACTIVITIES. TO CONTINUE ITS MISSION OF ACCELERATING MYELIN REPAIR TREATMENTS FOR MS PATIENTS, MRF WORKED TO SMOOTHLY REDUCE THE DEPTH AND BREADTH OF ITS PROGRAMS WHILE PRESERVING THE SCIENTIFIC RESULTS AND METHODS ACHIEVED OVER THE LAST 12 YEARS. MRF ALSO BEGAN TO ANALYZE HOW BEST TO HAVE AN IMPACT ON MYELIN REPAIR WITH MUCH LOWER FUTURE ANNUAL BUDGETS. FORM 990, PART VI, SECTION B, LINE 11 THE TAXPAYER'S ACCOUNTING FIRM FORWARDS THE FORM 990 TO THE CFO WHO THEN FORWARDS THE FORM 990 TO THE BOARD MEMBERS FOR THEIR REVIEW PRIOR TO FILING THE FORM 990. BOARD MEMBERS ARE ENCOURAGED TO REVIEW THE FORM AND TO FORWARD THEIR QUESTIONS, IF ANY, TO THE CONTROLLER OR CFO. FORM 990, PART VI, SECTION B, LINE 12C OFFICERS, DRECTORS AND KEY EMPLOYEES ARE COVERED. ANY AND ALL CONFLICTS ARE REVIEWED BY DISINTERESTED BOARD MEMBERS AND, IF NEEDED, BY LEGAL COUNSEL. PERSONS WITH A CONFLICT OF INTEREST WILL BE RESTRICTED FROM MAKING KEY DECISIONS FOR MRF AS THEY RELATE TO THE INTEREST UNLESS OTHERWISE APPROVED BY THE MAJORITY OF THE DISINTERESTED BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 15 CEO COMPENSATION IS DETERMINED BY THE INDEPENDENT COMPENSATION COMMITTEE. KEY EMPLOYEES' COMPENSATION IS DETERMINED BY AN ANNUAL REVIEW OF THE EMPLOYEE AND AN ANNUAL REVIEW OF THEIR COMPENSATION BY THE CEO. THIS INFORMATION IS ALSO SHARED WITH THE INDEPENDENT COMPENSATION COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE AVAILABLE ON OUR WEBSITE. GOVERNING DOCUMENTS AND POLICIES ARE AVAILABLE UPON REQUEST.